JUN 18, 2026 · REGULATORY LABEL UPDATE
FDA supplemental approval: Fentanyl (REMS)
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for fentanyl transdermal film products; this is a regulatory action, not a clinical trial, and does not report efficacy or safety trial outcomes.
Reported
Approval status date2026-06-18
Submission classREMS